Company Announcement

Share Purchase Plan - Quotation of Shares and Cheque Refunds

16 November 2011, Melbourne, Australia: Phosphagenics Limited (ASX code: “POH”) affirms that the issue of shares arising from the Share Purchase Plan (“the SPP”) has been completed and that the new 21,433,226 fully paid ordinary shares have been granted quotation by the ASX effective as of this morning.

Holding Statements reflecting the issue of the SPP shares together with refund cheques, where applicable and totaling $11,052,261.66, will be sent to the participating shareholders during next week.

Ends

Enquiries:

David Segal
Investor Relations Manger
Phosphagenics Limited
+61 3 9565 1103

About Phosphagenics

Phosphagenics is commercialising drug delivery applications based on its novel transdermal (drugs administered via skin) TPM® – Targeted Penetration Matrix technology. TPM® is a patient friendly and cost effective system used to deliver proven pharmaceutical and nutraceutical products.

The lead product advancing through clinical trials is an oxycodone matrix system for the relief of chronic pain.

Phosphagenics’ shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

www.phosphagenics.com
www.elixia.com.au